Protocols

Analysts project a big spike in COPD market as new drugs arrive; Valeant raises $930M in latest asset sale

→  The COPD drug market is expected to grow dramatically over the next decade, hitting $14.1 billion by 2025, according to GlobalData.  It was $9.9 billion in 2015. The growth will be fueled by increased diagnoses as well as new bronchodilator drug classes and anti-eosinophilic biologics.

→  Valeant is selling iNova for $930 million. The company is selling off assets in an attempt to reduce large piles of debt acquired under previous CEO Mike Pearson as he went on a deal-making spree. Pearson was replaced by Joseph Papa last year.

→  CytRx announced it plans to submit a rolling NDA under section 505(b)(2) New Drug Application (NDA) for aldoxorubicin, which has received orphan drug designation, in soft tissue sarcomas (STS). The drug flopped in 2016.

→  Exact Sciences Corporation $EXAS is selling 7m shares of common stock at a public offering price of $35 per share. It’s expected to close June 12.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

EvaluatePharma World Preview 2017